vs
Side-by-side financial comparison of BIOMARIN PHARMACEUTICAL INC (BMRN) and SERVICE CORP INTERNATIONAL (SCI). Click either name above to swap in a different company.
SERVICE CORP INTERNATIONAL is the larger business by last-quarter revenue ($1.1B vs $874.6M, roughly 1.3× BIOMARIN PHARMACEUTICAL INC). SERVICE CORP INTERNATIONAL runs the higher net margin — 14.3% vs -5.3%, a 19.7% gap on every dollar of revenue. On growth, BIOMARIN PHARMACEUTICAL INC posted the faster year-over-year revenue change (17.0% vs 1.7%). SERVICE CORP INTERNATIONAL produced more free cash flow last quarter ($87.2M vs $58.9M). Over the past eight quarters, BIOMARIN PHARMACEUTICAL INC's revenue compounded faster (16.1% CAGR vs 3.1%).
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies (ERTs). BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria (PKU).
International Distribution Services Limited is a British company providing postal and courier services. IDS was created in 2013 by the UK government as a new holding company of Royal Mail, and a majority of its shares were then sold on the London Stock Exchange, with the government initially retaining a 30 per cent at the time. As of April 2025, IDS is owned and operated by Czech-based EP Group, owned by Daniel Křetínský.
BMRN vs SCI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $874.6M | $1.1B |
| Net Profit | $-46.6M | $159.4M |
| Gross Margin | 68.5% | 28.0% |
| Operating Margin | -5.1% | 24.8% |
| Net Margin | -5.3% | 14.3% |
| Revenue YoY | 17.0% | 1.7% |
| Net Profit YoY | -137.3% | 5.3% |
| EPS (diluted) | $-0.22 | $1.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $874.6M | $1.1B | ||
| Q3 25 | $776.1M | $1.1B | ||
| Q2 25 | $825.4M | $1.1B | ||
| Q1 25 | $745.1M | $1.1B | ||
| Q4 24 | $747.3M | $1.1B | ||
| Q3 24 | $745.7M | $1.0B | ||
| Q2 24 | $712.0M | $1.0B | ||
| Q1 24 | $648.8M | $1.0B |
| Q4 25 | $-46.6M | $159.4M | ||
| Q3 25 | $-30.7M | $117.5M | ||
| Q2 25 | $240.5M | $122.9M | ||
| Q1 25 | $185.7M | $142.9M | ||
| Q4 24 | $124.9M | $151.4M | ||
| Q3 24 | $106.1M | $117.8M | ||
| Q2 24 | $107.2M | $118.2M | ||
| Q1 24 | $88.7M | $131.3M |
| Q4 25 | 68.5% | 28.0% | ||
| Q3 25 | 82.0% | 25.1% | ||
| Q2 25 | 81.8% | 25.5% | ||
| Q1 25 | 79.7% | 27.1% | ||
| Q4 24 | 81.8% | 28.0% | ||
| Q3 24 | 74.7% | 24.9% | ||
| Q2 24 | 81.7% | 24.9% | ||
| Q1 24 | 80.7% | 26.2% |
| Q4 25 | -5.1% | 24.8% | ||
| Q3 25 | -6.0% | 21.4% | ||
| Q2 25 | 33.5% | 21.1% | ||
| Q1 25 | 30.0% | 23.4% | ||
| Q4 24 | 21.6% | 24.0% | ||
| Q3 24 | 15.3% | 20.9% | ||
| Q2 24 | 16.9% | 21.4% | ||
| Q1 24 | 13.6% | 22.2% |
| Q4 25 | -5.3% | 14.3% | ||
| Q3 25 | -4.0% | 11.1% | ||
| Q2 25 | 29.1% | 11.5% | ||
| Q1 25 | 24.9% | 13.3% | ||
| Q4 24 | 16.7% | 13.8% | ||
| Q3 24 | 14.2% | 11.6% | ||
| Q2 24 | 15.1% | 11.4% | ||
| Q1 24 | 13.7% | 12.6% |
| Q4 25 | $-0.22 | $1.13 | ||
| Q3 25 | $-0.16 | $0.83 | ||
| Q2 25 | $1.23 | $0.86 | ||
| Q1 25 | $0.95 | $0.98 | ||
| Q4 24 | $0.65 | $1.02 | ||
| Q3 24 | $0.55 | $0.81 | ||
| Q2 24 | $0.55 | $0.81 | ||
| Q1 24 | $0.46 | $0.89 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3B | $243.6M |
| Total DebtLower is stronger | — | $5.1B |
| Stockholders' EquityBook value | $6.1B | $1.6B |
| Total Assets | $7.6B | $18.7B |
| Debt / EquityLower = less leverage | — | 3.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3B | $243.6M | ||
| Q3 25 | $1.3B | $241.3M | ||
| Q2 25 | $1.2B | $255.4M | ||
| Q1 25 | $1.0B | $227.2M | ||
| Q4 24 | $942.8M | $218.8M | ||
| Q3 24 | $675.4M | $185.4M | ||
| Q2 24 | $972.1M | $184.4M | ||
| Q1 24 | $747.0M | $205.6M |
| Q4 25 | — | $5.1B | ||
| Q3 25 | — | $5.0B | ||
| Q2 25 | — | $5.0B | ||
| Q1 25 | — | $4.7B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | — | $4.7B | ||
| Q2 24 | — | $4.7B | ||
| Q1 24 | — | $4.6B |
| Q4 25 | $6.1B | $1.6B | ||
| Q3 25 | $6.1B | $1.6B | ||
| Q2 25 | $6.0B | $1.6B | ||
| Q1 25 | $5.8B | $1.7B | ||
| Q4 24 | $5.7B | $1.7B | ||
| Q3 24 | $5.4B | $1.6B | ||
| Q2 24 | $5.3B | $1.5B | ||
| Q1 24 | $5.1B | $1.6B |
| Q4 25 | $7.6B | $18.7B | ||
| Q3 25 | $7.6B | $18.4B | ||
| Q2 25 | $7.5B | $18.0B | ||
| Q1 25 | $7.1B | $17.3B | ||
| Q4 24 | $7.0B | $17.4B | ||
| Q3 24 | $6.9B | $17.4B | ||
| Q2 24 | $7.1B | $16.8B | ||
| Q1 24 | $6.9B | $16.7B |
| Q4 25 | — | 3.10× | ||
| Q3 25 | — | 3.17× | ||
| Q2 25 | — | 3.19× | ||
| Q1 25 | — | 2.87× | ||
| Q4 24 | — | 2.83× | ||
| Q3 24 | — | 2.92× | ||
| Q2 24 | — | 3.05× | ||
| Q1 24 | — | 2.90× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $99.6M | $212.9M |
| Free Cash FlowOCF − Capex | $58.9M | $87.2M |
| FCF MarginFCF / Revenue | 6.7% | 7.8% |
| Capex IntensityCapex / Revenue | 4.7% | 11.3% |
| Cash ConversionOCF / Net Profit | — | 1.34× |
| TTM Free Cash FlowTrailing 4 quarters | $725.0M | $554.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $99.6M | $212.9M | ||
| Q3 25 | $368.7M | $252.3M | ||
| Q2 25 | $185.3M | $166.4M | ||
| Q1 25 | $174.4M | $311.1M | ||
| Q4 24 | $185.6M | $264.1M | ||
| Q3 24 | $221.5M | $263.8M | ||
| Q2 24 | $118.8M | $196.9M | ||
| Q1 24 | $47.0M | $220.1M |
| Q4 25 | $58.9M | $87.2M | ||
| Q3 25 | $340.2M | $150.7M | ||
| Q2 25 | $168.2M | $83.4M | ||
| Q1 25 | $157.6M | $233.0M | ||
| Q4 24 | $166.1M | $151.8M | ||
| Q3 24 | $203.0M | $162.8M | ||
| Q2 24 | $97.4M | $100.8M | ||
| Q1 24 | $20.9M | $140.3M |
| Q4 25 | 6.7% | 7.8% | ||
| Q3 25 | 43.8% | 14.2% | ||
| Q2 25 | 20.4% | 7.8% | ||
| Q1 25 | 21.2% | 21.7% | ||
| Q4 24 | 22.2% | 13.9% | ||
| Q3 24 | 27.2% | 16.1% | ||
| Q2 24 | 13.7% | 9.7% | ||
| Q1 24 | 3.2% | 13.4% |
| Q4 25 | 4.7% | 11.3% | ||
| Q3 25 | 3.7% | 9.6% | ||
| Q2 25 | 2.1% | 7.8% | ||
| Q1 25 | 2.3% | 7.3% | ||
| Q4 24 | 2.6% | 10.3% | ||
| Q3 24 | 2.5% | 10.0% | ||
| Q2 24 | 3.0% | 9.3% | ||
| Q1 24 | 4.0% | 7.6% |
| Q4 25 | — | 1.34× | ||
| Q3 25 | — | 2.15× | ||
| Q2 25 | 0.77× | 1.35× | ||
| Q1 25 | 0.94× | 2.18× | ||
| Q4 24 | 1.49× | 1.75× | ||
| Q3 24 | 2.09× | 2.24× | ||
| Q2 24 | 1.11× | 1.67× | ||
| Q1 24 | 0.53× | 1.68× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BMRN
| VOXZOGO | $273.4M | 31% |
| VIMIZIM | $205.5M | 24% |
| PALYNZIQ | $125.3M | 14% |
| NAGLAZYME | $120.2M | 14% |
| Other | $49.4M | 6% |
| ALDURAZYME | $49.4M | 6% |
| KUVAN | $23.3M | 3% |
| Royalty And Other | $15.2M | 2% |
| ROCTAVIAN | $12.8M | 1% |
SCI
| Cemetery | $510.9M | 46% |
| Funeral Matured Preneed Revenue | $196.5M | 18% |
| Cemetery Recognized Preneed Merchandise And Service Revenue | $107.4M | 10% |
| Cemetery Atneed Revenue | $104.9M | 9% |
| CA | $56.4M | 5% |
| Funeral Other Revenue | $54.6M | 5% |
| Cemetery Other Revenue | $40.2M | 4% |
| Nonfuneral Home Revenue | $28.1M | 3% |
| Non Funeral Home Preneed Sales Revenue | $22.0M | 2% |
